Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index (Q38929509)

7 September 2017

1 reference

title

Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index (English)

1 reference

7 September 2017

1 reference

1 reference

Graeme Meintjes

2

0 references

Gary Maartens

object named as

Gary Maartens

series ordinal

3

0 references

author name string

Sean Wasserman

series ordinal

1

1 reference

7 September 2017

17 August 2016

1 reference

Expert Review of Anti-infective Therapy

7 September 2017

1 reference

7 September 2017

14

1 reference

7 September 2017

901-915

1 reference

7 September 2017

10

1 reference

Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study

7 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

A systematic review of the cost and cost effectiveness of treatment for multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

1H nuclear magnetic resonance study of oxazolidinone binding to bacterial ribosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Activity of linezolid against Gram-positive cocci possessing genes conferring resistance to protein synthesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Pharmacological issues of linezolid: an updated critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Pharmacokinetics and tissue penetration of linezolid following multiple oral doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid penetration into cerebrospinal fluid and brain tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Drug concentration in lung tissue in multidrug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Intrapulmonary pharmacokinetics of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Intrapulmonary penetration of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

A review of linezolid: the first oxazolidinone antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Therapeutic drug monitoring of linezolid: a retrospective monocentric analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

High plasma linezolid concentration and impaired renal function affect development of linezolid-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Clarithromycin significantly increases linezolid serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Serotonin toxicity associated with the use of linezolid: a review of postmarketing data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Toxicity of extended courses of linezolid: results of an Infectious Diseases Society of America Emerging Infections Network survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid and serotonergic drug interactions: a retrospective survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Activity and interactions of levofloxacin, linezolid, ethambutol and amikacin in three-drug combinations against Mycobacterium tuberculosis isolates in a human macrophage model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro effect of three-drug combinations of antituberculous agents against multidrug-resistant Mycobacterium tuberculosis isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Oxazolidinones: activity, mode of action, and mechanism of resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Oxazolidinone antibiotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro and in vivo activities of three oxazolidinones against nonreplicating Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Activity of linezolid-containing regimens against multidrug-resistant tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid for XDR-TB--Final Study Outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Population pharmacokinetic analysis of linezolid in low body weight patients with renal dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Mitochondrial pharmacogenomics: barcode for antibiotic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

The origin and early evolution of mitochondria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Mitochondrial threshold effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Oxidative phosphorylation at the fin de siècle

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Mitochondrial toxicity associated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid-induced inhibition of mitochondrial protein synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Oxazolidinones inhibit cellular proliferation via inhibition of mitochondrial protein synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid-induced lactic acidosis in two liver transplant patients with the mitochondrial DNA A2706G polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

A new genetic polymorphism in the 16S ribosomal RNA gene of human mitochondrial DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid Trough Concentrations Correlate with Mitochondrial Toxicity-Related Adverse Events in the Treatment of Chronic Extensively Drug-Resistant Tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Fatal lactic acidosis after prolonged linezolid exposure for treatment of multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Peripheral neuropathy associated with prolonged use of linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid tolerability in multidrug-resistant tuberculosis: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid Surveillance Results for the United States (LEADER Surveillance Program 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Antimicrobial resistance to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro-selected linezolid-resistant Mycobacterium tuberculosis mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

First linezolid-resistant clinical isolates of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Resistance to linezolid caused by modifications at its binding site on the ribosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Ribosomal and non-ribosomal resistance to oxazolidinones: species-specific idiosyncrasy of ribosomal alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Differences in cell wall thickness between resistant and nonresistant strains of Mycobacterium tuberculosis: using transmission electron microscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Mutant prevention concentration: comparison of fluoroquinolones and linezolid with Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Meta-analysis of clinical studies supports the pharmacokinetic variability hypothesis for acquired drug resistance and failure of antituberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Linezolid in the treatment of osteomyelitis: results of compassionate use experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Population pharmacokinetics of linezolid in patients treated in a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

In vivo pharmacodynamics of a new oxazolidinone (linezolid)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Clinical outcomes of linezolid treatment for extensively drug-resistant tuberculosis in Beijing, China: a hospital-based retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Biomarkers for tuberculosis disease activity, cure, and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Therapeutic drug monitoring in the treatment of tuberculosis: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Limited sampling strategies for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Clinical validation of the analysis of linezolid and clarithromycin in oral fluid of patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Dried blood spots: a new tool for tuberculosis treatment optimization

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Dried blood spot analysis for therapeutic drug monitoring of linezolid in patients with multidrug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Tuberculosis--advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Conserving antibiotics for the future: new ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14787210.2016.1225498

10.1080/14787210.2016.1225498

21 January 2018

Identifiers

DOI

1 reference

7 September 2017

1 reference

PubMed ID

27532292